Elucidation of Thioredoxin as a Molecular Target for Antitumor Quinols
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Heteroaromatic quinols 4-(benzothiazol-2-yl)-4-hydroxycyclohexa-2,5-dienone (1) and 4-(1-benzenesulfonyl-1H-indol-2-yl)-4-hydroxycyclohexa-2,5-dienone (2) exhibit potent and selective antitumor activity against colon, renal, and breast carcinoma cell lines in vitro (GI50 < 500 nmol/L). In vivo growth inhibition of renal, colon, and breast xenografts has been observed. Profound G2-M cell cycle block accompanied down-regulation of cdk1 gene transcription was corroborated by decreased CDK1 protein expression following treatment of HCT 116 cells with growth inhibitory concentrations of 1 or 2. The chemical structure of the quinol pharmacophore 4-(hydroxycyclohexa-2,5-dienone) suggested that these novel agents would readily react with nucleophiles in a double Michael (β-carbon) addition. Indeed, COMPARE analysis within the National Cancer Institute database revealed a number of chemically related quinone derivatives that could potentially react with sulfur nucleophiles in a similar manner and suggested that thioredoxin/thioredoxin reductase signal transduction could be a putative target. Molecular modeling predicted covalent irreversible binding between quinol analogues and cysteine residues 32 and 35 of thioredoxin, thereby inhibiting enzyme activity. Binding has been confirmed, via mass spectrometry, between reduced human thioredoxin and 1. Microarray analyses of untreated HCT 116 cells and those exposed to either 1 (1 μmol/L) or 2 (500 nmol/L and 1 μmol/L) determined that of ≥10,000 cancer-related genes, expression of thioredoxin reductase was up-regulated >3-fold. Furthermore, quinols 1 and 2 inhibited insulin reduction, catalyzed by thioredoxin/thioredoxin reductase signaling in a dose-dependent manner (IC50 < 6 μmol/L). Results are consistent with a mechanism of action of novel antitumor quinols involving inhibition of the small redox protein thioredoxin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boyd, M. R., & Paull, K. D. (1995) · Drug Development Research · doi:10.1002/ddr.430340203 · Cited by 1,572
Cited by
From Selenium to Selenoproteins: Synthesis, Identity, and Their Role in Human Health
Papp, L. V., Lu, J., Holmgren, A., & Khanna, K. K. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1528 · Cited by 1,338
Mortimer, C. G., Wells, G., Crochard, J.-P., Stone, E. L., Bradshaw, T. D., Stevens, M. F. G., & Westwell, A. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050942k · Cited by 475
Self-citationRedox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities
Wondrak, G. T. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2541 · Cited by 462
Lu, J., Papp, L. V., Fang, J., Rodriguez-Nieto, S., Zhivotovsky, B., & Holmgren, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3310 · Cited by 326
Leong, C.-O., Vidnovic, N., DeYoung, M. P., Sgroi, D., & Ellisen, L. W. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30866 · Cited by 270
Metadata
- Authors
- Bradshaw, T. D., Matthews, C. S., Cookson, J., Chew, E.-H., Shah, M., Bailey, K., Monks, A., Harris, E., Westwell, A. D., Wells, G., Laughton, C. A., & Stevens, M. F. G.
- Venue
- Cancer Research
- Published
- 2005-05-01
- Volume
- 65
- Issue
- 9
- Pages
- 3911-3919
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2146955744
- Cited by
- 83
- References
- 1
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Elucidation of Thioredoxin as a Molecular Target for Antitumor Quinols. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-4141
- The paper
- Bradshaw, T. D., Matthews, C. S., Cookson, J., Chew, E.-H., Shah, M., Bailey, K., Monks, A., Harris, E., Westwell, A. D., Wells, G., Laughton, C. A., & Stevens, M. F. G. (2005). Elucidation of Thioredoxin as a Molecular Target for Antitumor Quinols. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-4141
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.